← Compound index
COMPOUND RECORD / VINPOTROPIL

VinpotropilВинпотропил

A fixed-dose combination of piracetam and vinpocetine investigated in cerebrovascular and cognitive research.

CognitionPerformance
Source linked

What the studies found

Observational study · 2010

MMSE rose 1.9 points in the 13-person stage II subgroup

Mean MMSE change in stage II subgroup
+1.9 points (n=13)Baseline 26.2 ± 2.4, day 30 28.2 ± 2.4. The published change is 1.9 points.Day 30
Patients rating response good or very good
15/20 (75%)Day 30
Objective neurological deficit
Unchanged.

Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.

More reported outcomes
Reported adverse effects
None in the 20 patients during 30 days.
Study notes · methods, sources and limitations

Participants or model 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.

Design Open single-cohort study, n=20. All 20 completed treatment and cognitive testing. Seven had stage I and 13 had stage II disease.

Important limitations

  • Repeated cognitive testing and background care may influence the change. The two publication versions describe the same patients. The study addressed chronic cerebral ischemia.
  • The 2012 republication credits the 2010 original (DOI 10.61788/njn.v1i12.14). A comparator is needed to estimate a treatment effect.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9):39–42. Reprinted in National Journal of Neurology (2012). · Publication record

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Observational study · 2010

Vinpotropil in chronic cerebrovascular cognitive impairment

Executive function and neurological symptoms
Improvement on repeat testing and symptom ratings was reported.Three months

The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.

Study notes · methods, sources and limitations

Participants or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.

Design Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.

Important limitations

  • The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.
  • The abstract does not report comparative effect sizes or adverse-event counts.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16. · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Study involving people · 2007

Vinpotropil during early ischemic stroke rehabilitation

Tolerability and convenience
Favorable patient reports for the fixed combination.No numerical neurological or functional outcome in the abstract.

Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.

Study notes · methods, sources and limitations

Participants or model Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.

Important limitations

  • The original tables are needed for group sizes, drug regimen and neurological or functional outcomes. The chronic cerebral ischemia reports involve a different clinical setting.
  • The original report is needed for enrollment, intervention schedules, and outcomes by arm.

Zh Nevrol Psikhiatr Im S S Korsakova. 2007;Suppl 21:52–56. · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Vinpotropil

Identity / background source ↗

Research background

Fixed vinpocetine–piracetam preparation studied in chronic cerebral ischemia and early stroke rehabilitation. Separate environmental and military comparisons are also indexed.

More study findings

Randomized study in people · 2008

Cortexin and other adjuncts in military combined-injury rehabilitation

Study of multiple preparations

Cortexin · work-capacity score
516.0±21.4 → 569.3±5.2Day 1 to day 14. Standard care 526.1±10.2 → 509.8±12.2.Reported p<0.05 versus standard care
Vinpotropil · work-capacity score
524.1±23.7 → 613.2±19.5Day 1 to day 14. Separate treatment arm.Reported p<0.05 versus standard care
Cortexin · clinician-rated anxiety
13.4±2.1 → 4.5±0.6Day 14. All arms showed some improvement.

Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.

More reported outcomes
Attrition
16 early discharges; zero attributed to adverse effectsThe abstract does not provide a comprehensive adverse-event table.
Study notes · methods, sources and limitations

Participants or model 317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.

Design Author-described double-blind randomized adjunctive study. Outcomes at days 7 and 14 included asthenia, anxiety, memory and tapping-based performance. Control included B-vitamin injections.

Reported study exposure
Cortexin 10 mg intramuscularly once daily, Mexidol 100 mg intramuscularly once daily, or Vinpotropil one oral capsule three times daily as separate adjuncts. Standard-care comparator included B1 and B6 injections.

Important limitations

  • Blinding implementation across different routes is unclear. Complete arm flow, attrition by arm and outcome units need the full dissertation.
  • This is short-term treatment research in hospitalized patients after trauma. The 60 analyzed are included within the 76 selected.

Kirov Military Medical Academy candidate dissertation author abstract · Kirov Military Medical Academy candidate dissertation author abstract

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2007

Meteoadaptogenic properties of nootrop drugs

Study of multiple preparations

Noopept
Favorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
Cortexin and Vinpotropil
Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
Dilept
Favorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Study notes · methods, sources and limitations

Participants or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)

Design Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.

Important limitations

  • The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open. This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review. Possible cohort overlap with the 2007 paper; not independent replication.
  • Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.

Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted · Bibliographic lead

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Environmental nootropic research
Research collection
Related nootropics & combinations · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

A 349-person multicenter report and a 20-person open study, plus a stroke rehabilitation report

Study methods

The chronic ischemia studies report outcomes during treatment. The stroke abstract gives no arm-level results.

Independent replication

Possible overlap with the Academy report

Source access

Journal abstracts and a republication of the 20-person study

Safety evidence

Original adverse-event tables are incomplete

Open a topic for the evidence assessment.

More findings, background and history

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2008 · EA009666B1 · Vinpotropil: vinpocetine plus piracetamFormulation · Vinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.7

Reported findings

The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.

Anxiety score
Vinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.721 daysSpielberger score; before/after significance is not a verified between-group treatment effect
Depression score
Vinpotropil 21.1 → 20.2; no significant differences reported in any group21 daysNeutral depression result retained
All reported results, comparisons and limitations →

Formulation. The patent describes the combination composition containing vinpocetine and piracetam.

A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.

Publication
EA009666B1 ↗ · 2008-02-28
Earliest priority / filing
2003-11-03 / 2004-10-29
Original applicant / assignee
Закрытое Акционерное Общество "Канонфарма Продакшн"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
34545985 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition exhibiting a cerebral vasodilatation and nootropic activity

Inventors: Not established from accessed metadata.

EA009666B1 · RU2262931C2 · WO2005041952A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Observational study · 2010

Vinpotropil in chronic cerebrovascular cognitive impairment

The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.

Study notes and original source
2010Uncontrolled human reportEnglish abstract

Vinpotropil in chronic cerebrovascular cognitive impairment

V. V. Zakharov · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16.

The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.

Results and tables

Reported findings and study design

Findings described in words

Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.

Population or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.

Dose, route and schedule

One capsule containing 5 mg vinpocetine and 400 mg piracetam, three times daily for three months.

Protocol source ↗ · Indexed English abstract of the original Russian journal report.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Executive function and neurological symptomsImprovement on repeat testing and symptom ratings was reported.Three months

The abstract does not report comparative effect sizes or adverse-event counts.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Source reviewed
Indexed English abstract of the original Russian journal report.
Study limitations
  • The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.

Reviewed 2026-11-14.

Read the source ↗

Observational study · 2010

Vinpotropil in early chronic cerebral ischemia: open study

Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.

Study notes and original source
2010Uncontrolled human reportFull text available

Vinpotropil in early chronic cerebral ischemia: open study

O. V. Vorob’eva, E. S. Tamarova · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9):39–42. Reprinted in National Journal of Neurology (2012).

Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.

Results and tables

Reported findings and study design

Open single-cohort study, n=20. All 20 completed treatment and cognitive testing. Seven had stage I and 13 had stage II disease.

Population or model 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.

Dose, route and schedule

Two capsules orally three times daily before meals for 30 days alongside existing care. Each capsule contained 5 mg vinpocetine and 400 mg piracetam.

Protocol source ↗ · Indexed original abstract and the credited 2012 journal republication.

Results · Indexed original abstract and the credited 2012 journal republication.
MeasureResultComparison, timing and statistics
Mean MMSE change in stage II subgroup+1.9 points (n=13)Baseline 26.2 ± 2.4, day 30 28.2 ± 2.4. The published change is 1.9 points. · Day 30
Patients rating response good or very good15/20 (75%)Day 30
Objective neurological deficitUnchanged.
Reported adverse effectsNone in the 20 patients during 30 days.

The 2012 republication credits the 2010 original (DOI 10.61788/njn.v1i12.14). A comparator is needed to estimate a treatment effect.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
Source reviewed
Indexed original abstract and the credited 2012 journal republication.
Study limitations
  • Repeated cognitive testing and background care may influence the change. The two publication versions describe the same patients. The study addressed chronic cerebral ischemia.

Reviewed 2026-11-14.

Read the source ↗

Study involving people · 2007

Vinpotropil during early ischemic stroke rehabilitation

Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.

Study notes and original source
2007Human study · design details unresolvedEnglish abstract

Vinpotropil during early ischemic stroke rehabilitation

A. N. Kuznetsov, V. D. Daminov · Zh Nevrol Psikhiatr Im S S Korsakova. 2007;Suppl 21:52–56.

Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.

Results and tables

Reported findings and study design

Findings described in words

Population or model Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Tolerability and convenienceFavorable patient reports for the fixed combination.No numerical neurological or functional outcome in the abstract.

The original report is needed for enrollment, intervention schedules, and outcomes by arm.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
Source reviewed
Indexed English abstract of the original Russian journal report.
Study limitations
  • The original tables are needed for group sizes, drug regimen and neurological or functional outcomes.
  • The chronic cerebral ischemia reports involve a different clinical setting.

Reviewed 2026-11-14.

Read the source ↗

Randomized study in people · 2008

Cortexin and other adjuncts in military combined-injury rehabilitation

Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.

Study notes and original source
2008Randomized trialRussian-language source

Cortexin and other adjuncts in military combined-injury rehabilitation

· Kirov Military Medical Academy candidate dissertation author abstract

Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations

I. Yu. Khabarov · Kirov Military Medical Academy candidate dissertation author abstract

Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.

Results and tables

Reported findings and study design

Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.

Author-described double-blind randomized adjunctive study. Outcomes at days 7 and 14 included asthenia, anxiety, memory and tapping-based performance. Control included B-vitamin injections.

Population or model 317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.

Dose, route and schedule

Cortexin 10 mg intramuscularly once daily, Mexidol 100 mg intramuscularly once daily, or Vinpotropil one oral capsule three times daily as separate adjuncts. Standard-care comparator included B1 and B6 injections.

Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.

Results · Author’s abstract transcription. Full dissertation and underlying records unavailable.
MeasureResultComparison, timing and statistics
Cortexin · work-capacity score516.0±21.4 → 569.3±5.2Day 1 to day 14. Standard care 526.1±10.2 → 509.8±12.2. · Reported p<0.05 versus standard care
Vinpotropil · work-capacity score524.1±23.7 → 613.2±19.5Day 1 to day 14. Separate treatment arm. · Reported p<0.05 versus standard care
Cortexin · clinician-rated anxiety13.4±2.1 → 4.5±0.6Day 14. All arms showed some improvement.
Attrition16 early discharges; zero attributed to adverse effectsThe abstract does not provide a comprehensive adverse-event table.

This is short-term treatment research in hospitalized patients after trauma. The 60 analyzed are included within the 76 selected.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.
Source reviewed
Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
  • Blinding implementation across different routes is unclear. Complete arm flow, attrition by arm and outcome units need the full dissertation.

Reviewed 2026-11-09.

Read the source ↗

Experiment described in a patent · 2008

Vinpotropil: vinpocetine plus piracetam — EA009666B1

The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.

Study notes and original source
2008Patent / reported experimentsFull text available

Vinpotropil: vinpocetine plus piracetam — EA009666B1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

· EA009666B1 · patent family 34545985

The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.

Results and tables

Reported patent results

Reported findings

The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.

Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.

Population or model Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.

Results · Clinical comparison, exclusions and psychological-status Table 9.
MeasureResultComparison, timing and statistics
Anxiety scoreVinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.7Spielberger score; before/after significance is not a verified between-group treatment effect · 21 days
Depression scoreVinpotropil 21.1 → 20.2; no significant differences reported in any groupNeutral depression result retained · 21 days
Withdrawals and gastric symptoms2 main-group and 6 comparator-group exclusions; gastric/dyspeptic complaints reported in 5% fixed-combination versus 20% separate-combination groupGroup denominators and analysis of withdrawals need original-trial verification

Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.
  • Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Controlled study in people · 2007

Meteoadaptogenic properties of peptide drugs in healthy volunteers

A program involving 127 healthy men compared four preparations under cold, heat and simulated altitude. Results varied by compound and test.

Study notes and original source
2007Clinical trial / comparisonFull text available

Meteoadaptogenic properties of peptide drugs in healthy volunteers

Format: Original journal PDF · Reviewed: Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open

P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov · Eksp Klin Farmakol. 70(6):41–47

Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

Results and tables

Reported findings and study design

Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.

Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage

Results · Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
MeasureResultComparison, timing and statistics
Noopept PWC170 in cold189 ± 10 versus 162 ± 2Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 in heat188 ± 6 versus 152 ± 1Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept arithmetic errors in heat0 ± 0 versus 0.8 ± 0.2Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control
Noopept state / trait anxiety in heat27 ± 3 / 27 ± 2Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 at simulated altitude197 ± 8 versus 154 ± 3Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control
Noopept activity self-rating in heat5.9 ± 0.4 versus 4.2 ± 0.2Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber
Cold chamber (−10°C): selected reported rows
Cold chamber (−10°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5153 ± 71.5 ± 0.0110.5 ± 1.21.2 ± 0.833 ± 331 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 1b155 ± 1b1.5 ± 0.0019.3 ± 1.71.5 ± 0.633 ± 331 ± 45.6 ± 0.45.3 ± 0.35.7 ± 0.5
Before chamberVinpotropil44 ± 3219 ± 9ab1.6 ± 0.01ab10.5 ± 1.02.1 ± 0.935 ± 332 ± 35.1 ± 0.35.0 ± 0.24.8 ± 0.5
Before chamberNoopept46 ± 3189 ± 3ab1.6 ± 0.01ab9.2 ± 1.20.4 ± 0.228 ± 2a27 ± 26.0 ± 0.96.3 ± 0.86.2 ± 0.7
Before chamberDilept42 ± 1b176 ± 1ab1.5 ± 0.0210.8 ± 1.80.8 ± 0.428 ± 2a28 ± 36.2 ± 0.75.4 ± 0.75.8 ± 0.3
Before chamberPlacebo48 ± 2159 ± 31.5 ± 0.019.7 ± 0.71.2 ± 0.631 ± 431 ± 35.6 ± 0.25.2 ± 0.35.6 ± 0.4
In chamberHistorical no-drug control45 ± 5165 ± 71.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin45 ± 3210 ± 7ab1.6 ± 0.02ab11.0 ± 1.90.3 ± 0.3ab38 ± 431 ± 45.2 ± 0.34.7 ± 0.45.1 ± 0.4
In chamberVinpotropil45 ± 2219 ± 13ab1.6 ± 0.02ab7.5 ± 0.8b0.5 ± 0.2ab36 ± 228 ± 3a4.9 ± 0.3b4.9 ± 0.15.1 ± 0.3
In chamberNoopept44 ± 2189 ± 10ab1.6 ± 0.02ab10.6 ± 1.51.6 ± 0.630 ± 3a27 ± 3a5.3 ± 0.36.0 ± 1.1a6.4 ± 0.8
In chamberDilept41 ± 1ab182 ± 5ab1.7 ± 0.01ab10.8 ± 1.90.8 ± 0.4a29 ± 3a28 ± 3a5.9 ± 0.5a5.3 ± 0.3a5.4 ± 0.6
In chamberPlacebo47 ± 2162 ± 21.5 ± 0.0110.0 ± 0.61.2 ± 0.533 ± 332 ± 35.4 ± 0.25.1 ± 0.45.5 ± 0.3

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Heat chamber (+45°C): selected reported rows
Heat chamber (+45°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control47 ± 3161 ± 41.5 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin43 ± 2181 ± 5ab1.6 ± 0.01ab11.5 ± 1.60.67 ± 0.235 ± 332 ± 35.1 ± 0.34.9 ± 0.24.8 ± 0.5
Before chamberVinpotropil45 ± 2189 ± 9ab1.6 ± 0.02ab10.7 ± 1.00.9 ± 0.429 ± 326 ± 35.9 ± 0.35.8 ± 0.2ab5.9 ± 0.3
Before chamberNoopept48 ± 3182 ± 3ab1.6 ± 0.01ab9.6 ± 1.30.8 ± 0.428 ± 3a27 ± 36.1 ± 0.2a6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberDilept44 ± 2180 ± 7ab1.6 ± 0.01ab9.7 ± 1.80.7 ± 0.226 ± 3ab28 ± 35.4 ± 0.24.6 ± 0.5b4.9 ± 0.2
Before chamberPlacebo46 ± 2164 ± 21.5 ± 0.0111.0 ± 0.61.0 ± 0.132 ± 330 ± 35.5 ± 0.25.3 ± 0.25.5 ± 0.5
In chamberHistorical no-drug control47 ± 4151 ± 51.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin39 ± 1a155 ± 91.5 ± 0.029.6 ± 1.10.8 ± 0.7a36 ± 228 ± 3a4.9 ± 0.34.9 ± 0.1a5.1 ± 0.3
In chamberVinpotropil41 ± 2a202 ± 11ab1.6 ± 0.02ab10.3 ± 1.10.7 ± 0.4a31 ± 327 ± 3ab5.7 ± 0.2ab5.6 ± 0.2ab5.9 ± 0.3b
In chamberNoopept44 ± 3188 ± 6ab1.6 ± 0.01ab12.0 ± 1.40 ± 0ab27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberDilept42 ± 2174 ± 9ab1.5 ± 0.01ab10.5 ± 0.90.8 ± 0.5a27 ± 3ab28 ± 2ab5.1 ± 0.34.6 ± 0.2a4.9 ± 0.2
In chamberPlacebo42 ± 4152 ± 11.5 ± 0.0110.9 ± 1.30.8 ± 0.234 ± 333 ± 35.3 ± 0.24.9 ± 0.35.3 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Simulated altitude (3,000 m): selected reported rows
Simulated altitude (3,000 m): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5151 ± 41.3 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 2170 ± 5a1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.1234 ± 332 ± 35.6 ± 0.35.1 ± 0.25.5 ± 0.3
Before chamberVinpotropil46 ± 2195 ± 5ab1.6 ± 0.01ab9.0 ± 0.50.5 ± 0.228 ± 327 ± 36.1 ± 0.2ab6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberNoopept47 ± 3202 ± 3ab1.6 ± 0.01ab11.2 ± 0.60.2 ± 0.229 ± 326 ± 25.9 ± 0.35.8 ± 0.2a5.9 ± 0.3
Before chamberDilept41 ± 1181 ± 3ab1.6 ± 0.01ab14.2 ± 3.01.0 ± 0.627 ± 3a28 ± 26.2 ± 0.2ab5.8 ± 0.1a5.8 ± 0.2
Before chamberPlacebo46 ± 4162 ± 51.5 ± 0.0110.1 ± 0.80.6 ± 0.133 ± 330 ± 35.5 ± 0.25.6 ± 0.25.6 ± 0.4
In chamberHistorical no-drug control46 ± 4145 ± 51.3 ± 0.019.8 ± 1.93 ± 0.638 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin41 ± 2170 ± 6ab1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.2a34 ± 332 ± 35.4 ± 0.25.0 ± 0.2ab5.4 ± 0.2
In chamberVinpotropil44 ± 2196 ± 6ab1.6 ± 0.01ab10.4 ± 0.90.8 ± 0.3a27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberNoopept45 ± 3197 ± 8ab1.6 ± 0.01ab11.4 ± 1.72.2 ± 2.231 ± 4a27 ± 3ab5.7 ± 0.2a5.6 ± 0.2ab5.9 ± 0.3
In chamberDilept41 ± 1186 ± 6ab1.6 ± 0.01ab12.6 ± 2.50.6 ± 0.4a28 ± 3a28 ± 3ab6.3 ± 0.2ab5.6 ± 0.3ab6.1 ± 0.3ab
In chamberPlacebo46 ± 4154 ± 31.5 ± 0.019.5 ± 1.00.6 ± 0.233 ± 334 ± 35.4 ± 0.34.6 ± 0.15.6 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
Source reviewed
Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.
Study limitations
  • Random allocation and blinding not established; historical controls and baseline differences limit attribution.
  • Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
  • Experimental intranasal peptide preparations are not equivalent to marketed oral products.
  • No validated protection from heat illness, operational accidents or long-term harm.
  • The Academy report may cover the same participants.

Reviewed 2026-11-08.

Read the source ↗

Comparison in people · 2007

Meteoadaptogenic properties of nootrop drugs

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Study notes and original source
2007Human comparative studyBibliographic record

Meteoadaptogenic properties of nootrop drugs

V. P. Ganapolsky, A. A. Elistratov, P. V. Alexandrov, P. D. Shabanov, E. G. Mokeeva, E. A. Mitin, V. I. Kruglov · Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted

The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.

Results and tables

Reported findings and study design

Qualitative, stressor-specific comparisons.

Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.

Population or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)

Results · Publisher abstract; full tables not recovered
MeasureResultComparison, timing and statistics
NoopeptFavorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
Cortexin and VinpotropilCortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
DileptFavorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.

Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
Source reviewed
Publisher metadata and Russian abstract checked. A related manufacturer-hosted PDF is indexed, but direct download timed out; the PDF contents were not appraised.
Study limitations
  • The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open.
  • This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review.
  • Possible cohort overlap with the 2007 paper; not independent replication.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗